IRIS Accounts Production v24.2.0.383 11275607 Board of Directors 1.1.23 31.12.23 31.12.23 false true true false false true false Ordinary A 0.01000 Ordinary B 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh112756072022-12-31112756072023-12-31112756072023-01-012023-12-31112756072021-12-31112756072022-01-012022-12-31112756072022-12-3111275607ns15:EnglandWales2023-01-012023-12-3111275607ns14:PoundSterling2023-01-012023-12-3111275607ns10:Director12023-01-012023-12-3111275607ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3111275607ns10:FRS1022023-01-012023-12-3111275607ns10:Audited2023-01-012023-12-3111275607ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport2023-01-012023-12-3111275607ns10:LargeMedium-sizedCompaniesRegimeForAccounts2023-01-012023-12-3111275607ns10:FullAccounts2023-01-012023-12-3111275607ns10:OrdinaryShareClass12023-01-012023-12-3111275607ns10:OrdinaryShareClass22023-01-012023-12-3111275607ns10:Director52023-01-012023-12-3111275607ns10:CompanySecretary12023-01-012023-12-3111275607ns10:RegisteredOffice2023-01-012023-12-3111275607ns10:Director22023-01-012023-12-3111275607ns10:Director32023-01-012023-12-3111275607ns10:Director42023-01-012023-12-3111275607ns5:CurrentFinancialInstruments2023-12-3111275607ns5:CurrentFinancialInstruments2022-12-3111275607ns5:ShareCapital2023-12-3111275607ns5:ShareCapital2022-12-3111275607ns5:SharePremium2023-12-3111275607ns5:SharePremium2022-12-3111275607ns5:RetainedEarningsAccumulatedLosses2023-12-3111275607ns5:RetainedEarningsAccumulatedLosses2022-12-3111275607ns5:ShareCapital2021-12-3111275607ns5:RetainedEarningsAccumulatedLosses2021-12-3111275607ns5:SharePremium2021-12-3111275607ns5:ShareCapital2022-01-012022-12-3111275607ns5:SharePremium2022-01-012022-12-3111275607ns5:RetainedEarningsAccumulatedLosses2022-01-012022-12-3111275607ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-311127560712023-01-012023-12-3111275607ns5:ReportableOperatingSegment12023-01-012023-12-3111275607ns5:ReportableOperatingSegment12022-01-012022-12-3111275607ns5:TotalReportableOperatingSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3111275607ns5:TotalReportableOperatingSegmentsIncludingAnyUnallocatedAmount2022-01-012022-12-3111275607ns15:UnitedKingdom2023-01-012023-12-3111275607ns15:UnitedKingdom2022-01-012022-12-3111275607ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3111275607ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2022-01-012022-12-3111275607ns5:OwnedAssets2023-01-012023-12-3111275607ns5:OwnedAssets2022-01-012022-12-3111275607122023-01-012023-12-3111275607122022-01-012022-12-3111275607132023-01-012023-12-3111275607132022-01-012022-12-3111275607142023-01-012023-12-3111275607142022-01-012022-12-3111275607152023-01-012023-12-3111275607152022-01-012022-12-3111275607ns10:OrdinaryShareClass12022-01-012022-12-3111275607ns10:OrdinaryShareClass22022-01-012022-12-3111275607ns5:FurnitureFittings2022-12-3111275607ns5:FurnitureFittings2023-01-012023-12-3111275607ns5:FurnitureFittings2023-12-3111275607ns5:FurnitureFittings2022-12-3111275607ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3111275607ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3111275607ns5:Non-currentFinancialInstruments2023-12-3111275607ns5:Non-currentFinancialInstruments2022-12-3111275607ns5:CurrentFinancialInstruments2023-01-012023-12-3111275607ns5:WithinOneYear2023-12-3111275607ns5:WithinOneYear2022-12-3111275607ns5:BetweenOneFiveYears2023-12-3111275607ns5:BetweenOneFiveYears2022-12-3111275607ns5:AllPeriods2023-12-3111275607ns5:AllPeriods2022-12-3111275607ns10:OrdinaryShareClass12023-12-3111275607ns10:OrdinaryShareClass22023-12-311127560712023-01-012023-12-31
REGISTERED NUMBER: 11275607 (England and Wales)















DATAPHARM LIMITED

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023






DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 December 2023










Page

Company Information 1

Report of the Directors 2

Report of the Independent Auditors 4

Statement of Comprehensive Income 8

Balance Sheet 9

Statement of Changes in Equity 10

Notes to the Financial Statements 11


DATAPHARM LIMITED

COMPANY INFORMATION
for the year ended 31 December 2023







Directors: R Cooper
J P G Wigg





Secretary: K Webster





Registered office: Cassini Court
Randalls Way
Leatherhead
Surrey
KT22 7TW





Registered number: 11275607 (England and Wales)





Auditors: Bennewith 2018 Limited
Statutory Auditors
Upper Ground Floor
18 Farnham Road
Guildford
Surrey
GU1 4XA

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

REPORT OF THE DIRECTORS
for the year ended 31 December 2023


The directors present their report with the financial statements of the company for the year ended 31 December 2023.

Principal activity
The principal activity of the company in the year under review was that of the collation and distribution of information and also the provision of regulatory and compliance software solutions to the healthcare and pharmaceutical industry.

Dividends
Dividends of £2,095,105 were paid during the year. No dividends were distributed in the prior year.

Events since the end of the year
Information relating to events since the end of the year is given in the notes to the financial statements.

Directors
The directors who have held office during the period from 1 January 2023 to the date of this report are as follows:

S M Abrams - resigned 1 March 2023
N J S Knight - resigned 30 June 2023
R Cooper - appointed 1 March 2023
P D Facchino - appointed 26 January 2023
J P G Wigg - appointed 30 June 2023

P D Facchino resigned on 1 July 2024 being after 31 December 2023 but prior to the date of this report.

Statement of directors' responsibilities
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

REPORT OF THE DIRECTORS
for the year ended 31 December 2023


Statement as to disclosure of information to auditors
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

On behalf of the board:





R Cooper - Director


24 September 2024

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
DATAPHARM LIMITED


Opinion
We have audited the financial statements of Datapharm Limited (the 'company') for the year ended 31 December 2023 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 December 2023 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
DATAPHARM LIMITED


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
DATAPHARM LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

As part of our audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
DATAPHARM LIMITED


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




A J Bennewith FCA, FCPA, FFA, FFTA, FIPA, DChA, FRSA (Senior Statutory Auditor)
for and on behalf of Bennewith 2018 Limited
Statutory Auditors
Upper Ground Floor
18 Farnham Road
Guildford
Surrey
GU1 4XA

24 September 2024

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

STATEMENT OF COMPREHENSIVE INCOME
for the year ended 31 December 2023

2023 2022
Notes £    £   

TURNOVER 4 7,617,712 6,090,639

Cost of sales (509,939 ) (652,573 )
GROSS PROFIT 7,107,773 5,438,066

Administrative expenses (6,350,341 ) (4,939,679 )
757,432 498,387

Other operating income 307,245 131,094
OPERATING PROFIT 6 1,064,677 629,481

Interest receivable and similar income 101,295 12,283
PROFIT BEFORE TAXATION 1,165,972 641,764

Tax on profit 7 (121,617 ) (142,074 )
PROFIT FOR THE FINANCIAL YEAR 1,044,355 499,690

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR THE
YEAR

1,044,355

499,690

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

BALANCE SHEET
31 December 2023

2023 2022
Notes £    £   
FIXED ASSETS
Tangible assets 9 251,693 24,021

CURRENT ASSETS
Debtors 10 7,752,566 4,403,262
Cash at bank 5,329,951 6,454,116
13,082,517 10,857,378
CREDITORS
Amounts falling due within one year 11 (10,988,151 ) (7,484,590 )
NET CURRENT ASSETS 2,094,366 3,372,788
TOTAL ASSETS LESS CURRENT LIABILITIES 2,346,059 3,396,809

CAPITAL AND RESERVES
Called up share capital 13 902 902
Share premium 127,431 127,431
Retained earnings 2,217,726 3,268,476
SHAREHOLDERS' FUNDS 2,346,059 3,396,809

The financial statements were approved by the Board of Directors and authorised for issue on 24 September 2024 and were signed on its behalf by:





R Cooper - Director


DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

STATEMENT OF CHANGES IN EQUITY
for the year ended 31 December 2023

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1 January 2022 710 2,768,786 - 2,769,496

Changes in equity
Issue of share capital 192 - 127,431 127,623
Total comprehensive income - 499,690 - 499,690
Balance at 31 December 2022 902 3,268,476 127,431 3,396,809

Changes in equity
Dividends - (2,095,105 ) - (2,095,105 )
Total comprehensive income - 1,044,355 - 1,044,355
Balance at 31 December 2023 902 2,217,726 127,431 2,346,059

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2023


1. STATUTORY INFORMATION

Datapharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements are prepared under the historical cost convention and modified to include certain items at fair value as explained further below.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows.

Going concern
The financial statements have been prepared on a going concern basis which is considered appropriate by the directors. There are no material uncertainties, of which the directors are aware in making their assessment, relating to events or conditions that may cast significant doubt upon the entity’s ability to continue as a going concern. The company maintains healthy cash balances and a strong cash flow position with subscription revenue invoiced in advance.

Turnover
Turnover is measured at the fair value of the consideration receivable for the sale of services in the ordinary course of the business, excluding discounts and value added tax. Where the company enters a contract for the provision of services which extend over a period of time, turnover is recognised in the period in which services are provided in accordance with the stage of completion of the transaction.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Office equipment - 50% on cost
Fixtures & fittings - 20% on cost

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The assets residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date.

On disposal the difference between net proceeds and carrying amount of the item sold is recognised in administrative expenses.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


2. ACCOUNTING POLICIES - continued

Financial instruments
Financial instruments are classified by the directors as basic or other following the conditions in FRS 102 Section 11. Basic financial instruments are recognised at amortised cost. The company has no other financial instruments.

Trade debtors are recognised and carried forward at invoiced amounts less provision for doubtful debts. All other debtors are recognised at transaction price less impairment if applicable.

Cash at bank and in hand comprises of cash that is readily available for use within the business and is held at financial institutions or as cash in hand.

Creditors falling due within one year are measured and carried forward at the transaction price.

Taxation
Taxation for the year comprises current and deferred tax. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.

Where applicable, the company claims the research and development expenditure credit available and this is shown within other operating income with the relevant tax charge reported within taxation. This treatment has been applied retrospectively as the credit was previously reported directly within taxation.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Operating leases
Rentals paid under operating leases are charged to the profit or loss on a straight line basis over the term of the lease.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


3. SIGNIFICANT JUDGEMENTS AND ESTIMATES

The preparation of the financial statements requires management to make judgements, estimates and assumptions in the application of accounting policies that affect reported amounts of assets, liabilities and profit and loss. In preparing these financial statements, management have made the following key judgements and estimates which are significant to the financial statements.

Recoverability of trade debtors
Trade debtors are recognised to the extent that they are judged recoverable. Provisions are made specifically against invoices where recoverability is uncertain.

Management make allowances for doubtful debts each year based on an assessment of the recoverability of debtors. Allowances are applied to debtors where events or changes in circumstances indicate that the carrying amounts may not be recoverable. Client creditworthiness, current economic trends, ageing of the debt and management experience are all considered when providing for doubtful debts.

The amount of the provision recognised in the profit or loss is the excess of the asset's carrying amount and the present value of estimated future cash flows.

Recoverability of intercompany balances
Management have made key judgements regarding the recoverability of related party debts. The recoverability of debts is assessed by reference to the related company performance and profit forecasts, and adjustments to the provisions are made as required.

Leasing
Management determine whether leases entered into are an operating or finance lease. These decisions depend on an assessment of whether the risks and rewards of ownership have been transferred from the lessor to the company and are assessed on a lease by lease basis. The transfer of risk is assessed by reference to the evaluation of the terms and conditions of the arrangement, the estimated useful life of the asset and whether an option to purchase exists at the end of the lease term.

4. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by class of business is given below:

2023 2022
£    £   
Provision of data services 7,617,712 6,090,639
7,617,712 6,090,639

An analysis of turnover by geographical market is given below:

2023 2022
£    £   
United Kingdom 6,627,409 5,457,714
Rest of World 990,303 632,925
7,617,712 6,090,639

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


5. EMPLOYEES AND DIRECTORS
2023 2022
£    £   
Wages and salaries 2,327,760 1,844,437
Social security costs 280,019 238,433
Other pension costs 133,950 97,123
2,741,729 2,179,993

The average number of employees during the year was as follows:
2023 2022

Administration 8 8
Client support 13 11
Product group 17 12
Directors 3 3
41 34

2023 2022
£    £   
Directors' remuneration 79,503 49,582
Directors' pension contributions to money purchase schemes 6,507 6,823

During the prior year, following the acquisition of Datapharm Limited by Summer Bidco Limited, the directors' employment contracts transferred to Summer Bidco Limited.

One director exercised share options during the year ended 31 December 2022.

6. OPERATING PROFIT

The operating profit is stated after charging:

2023 2022
£    £   
Depreciation - owned assets 20,978 45,786
Auditors remuneration 15,000 15,000
Onetime costs for strategic review and sale of company - 729,718
Operating lease rentals 96,047 53,526
Defined pension contributions 133,950 97,123

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


7. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2023 2022
£    £   
Current tax:
UK corporation tax 121,617 24,074

Deferred tax - 118,000
Tax on profit 121,617 142,074

UK corporation tax has been charged at 23.52% (2022 - 19%).

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2023 2022
£    £   
Profit before tax 1,165,972 641,764
Profit multiplied by the standard rate of corporation tax in the UK of
23.521% (2022 - 19%)

274,248

121,935

Effects of:
Expenses not deductible for tax purposes 6,968 52,198
Adjustments to tax charge in respect of previous periods - 2,691
Tax rate changes - 27,474
differences
Share options - (3,273,434 )
Deferred tax not recognised (159,599 ) 3,211,210
Total tax charge 121,617 142,074

As at 31 December 2023 the company has corporation tax losses of £16,188,281 (2022: £16,872,265) and timing differences of £130,191 (2022: £18,840) carried forward, resulting in a deferred tax asset of £4,079,618 (2022: £4,222,776). This deferred tax asset has not been recognised on the basis that the group is forecasted to generate sufficient tax losses to relieve any future taxable profits and therefore the tax losses brought forward are not expected to be utilised.

8. DIVIDENDS
2023 2022
£    £   
Ordinary A shares of £0.01 each
Interim 1,801,116 -
Ordinary B shares of £0.01 each
Interim 293,989 -
2,095,105 -

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


9. TANGIBLE FIXED ASSETS
Office
equipment
£   
Cost
At 1 January 2023 472,078
Additions 248,650
At 31 December 2023 720,728
Depreciation
At 1 January 2023 448,057
Charge for year 20,978
At 31 December 2023 469,035
Net book value
At 31 December 2023 251,693
At 31 December 2022 24,021

10. DEBTORS
2023 2022
£    £   
Amounts falling due within one year:
Trade debtors 4,192,108 2,865,092
Amounts owed by group undertakings 1,764,838 1,209,017
Other debtors 334,731 141,554
Prepayments and accrued income 418,807 187,599
6,710,484 4,403,262

Amounts falling due after more than one year:
Amounts owed by group undertakings 1,042,082 -

Aggregate amounts 7,752,566 4,403,262

The amounts owed by group undertakings falling due after more than one year are subject to 12% interest per annum and are repayable in August 2025.

All other amounts owed by group undertakings are interest free and repayable on demand.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 110,515 170,897
Amounts owed to group undertakings 49,351 2,470
Taxation and social security 978,291 617,547
Other creditors 1,013 3,089
Accruals and deferred income 9,848,981 6,690,587
10,988,151 7,484,590

The amounts owed to group undertakings are subject to an arm's lenth market rate of interest and repayable on demand.

12. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2023 2022
£    £   
Within one year 119,681 57,143
Between one and five years 769,380 28,571
889,061 85,714

13. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
77,500 Ordinary A £0.01 775 775
12,650 Ordinary B £0.01 127 127
902 902

The following shares were allotted and fully paid during the year ended 31 December 2022 further to the exercise of employee share options:
- 6,500 Ordinary A shares of £0.01 each at par;
- 12,650 Ordinary B shares of £0.01 each of which 6,650 were allotted at par, 3,450 were at a premium of £8.31 per share and 2,550 were at a premium of £38.73 per share.

The Ordinary A shares and Ordinary B shares rank pari passu in relation to dividend payments and any other distributions. Only the Ordinary A shares carry voting rights.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2023


14. ULTIMATE PARENT COMPANY

On 23 February 2022, Summer Bidco Limited, which is registered in England and Wales, acquired a 100%
shareholding in Datapharm Limited. As a result of this transaction, Summer Topco Limited became the ultimate
parent company.

The accounts of Datapharm Limited are included in the consolidated group accounts of Summer Topco Limited. Summer Topco Limited is registered in England and Wales and its financial statements can be obtained from its registered office at Cassini Court, Randalls Way, Leatherhead, Surrey, KT22 7TW.

15. PENSION COMMITMENTS

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Contributions totalling £Nil (2022: £Nil) were payable to the fund at the balance sheet date.

16. POST BALANCE SHEET EVENTS

The company acquired the entire share capital of Original Digital Limited on 19 July 2024. The total consideration was estimated to be £2.3m and included cash consideration, deferred consideration and attributable fees, funded from the company's existing cash reserves.

17. ULTIMATE CONTROLLING PARTY

As from 23 February 2022, the ultimate controlling party is CGE Partners LLP, a limited liability partnership
registered in England and Wales.